A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine

NCT01675284 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Bird Flu
Avian Influenza
Influenza A(H5N1)

Interventions

BIOLOGICAL: AT-301

Sponsor

Medigen Biotechnology Corporation